The company manages three funds worth 120m euros for European private and institutional investors and prefers to lead or co-lead financing rounds ranging from 5m to 40m euros, with a total commitment of up to 10m euros per portfolio company. EMBL Ventures values open and prompt communication with its investors and aims to generate maximum returns. Based in Heidelberg, the company invests throughout Europe in companies that create significant commercial opportunities in new therapeutic treatment modalities, pharmaceuticals, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. In addition to investment activities, EMBL Ventures offers consulting services to life science companies, focusing on company building, M&A, corporate strategy, in- and out-licensing, and has a strong investment track record, experience in building successful companies, closing collaboration and licensing agreements, M&A's, and IPOs.